
Outlook Therapeutics has announced the Scottish Medicines Consortium (SMC) approval of Lytenava (bevacizumab gamma) for the treatment of wet age-related …

A report commissioned by the European Union Intellectual Property Office has shown that a staggering amount of money, €10.2 billion, …

